ScoreComparison
Why is Denali Therapeutics, Inc. ?
1
Poor Management Efficiency with a low ROE of 1.05%
- The company has been able to generate a Return on Equity (avg) of 1.05% signifying low profitability per unit of shareholders funds
2
Positive results in Jun 26
- NET PROFIT(HY) Higher at USD -256 MM
- NET SALES(9M) Higher at USD 3.6 MM
- INVENTORY TURNOVER RATIO(HY) Highest at 7.28 times
3
Risky -
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of 56.78%, its profits have fallen by -21.2%
4
Reducing Promoter Confidence
- Promoters have decreased their stake in the company by -3.62% over the previous quarter and currently hold 1.98% of the company
- Promoters decreasing their stake may signify reduced confidence in the future of the business
5
Market Beating Performance
- The stock has generated a return of 56.78% in the last 1 year, much higher than market (S&P 500) returns of 15.76%
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Denali Therapeutics, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Denali Therapeutics, Inc. for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
Denali Therapeutics, Inc.
56.78%
-0.05
57.60%
S&P 500
15.76%
1.20
13.17%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
-100.00%
EBIT Growth (5y)
-254.68%
EBIT to Interest (avg)
-271.59
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.72
Sales to Capital Employed (avg)
0.21
Tax Ratio
0.01%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
1.05%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
2.84
EV to EBIT
-3.64
EV to EBITDA
-3.72
EV to Capital Employed
13.01
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-357.30%
ROE (Latest)
-50.56%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Mildly Bullish
Dow Theory
Mildly Bullish
No Trend
OBV
No Trend
Mildly Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend14What is working for the Company
NET PROFIT(HY)
Higher at USD -256 MM
NET SALES(9M)
Higher at USD 3.6 MM
INVENTORY TURNOVER RATIO(HY)
Highest at 7.28 times
DEBTORS TURNOVER RATIO(HY)
Highest at 1.06 times
OPERATING PROFIT(Q)
Highest at USD -125.14 MM
EPS(Q)
Highest at USD -0.68
-6What is not working for the Company
OPERATING CASH FLOW(Y)
Lowest at USD -434.04 MM
ROCE(HY)
Lowest at -54.93%
RAW MATERIAL COST(Y)
Grown by 5,239% (YoY
CASH AND EQV(HY)
Lowest at USD 1,698.15 MM
Here's what is working for Denali Therapeutics, Inc.
Net Sales
At USD 3.6 MM has Grown at inf%
Year on Year (YoY)MOJO Watch
Sales trend is very positive
Net Sales (USD MM)
Net Profit
Higher at USD -256 MM
than preceding 12 month period ended Jun 2026MOJO Watch
In the half year the company has already crossed Net Profit of the previous twelve months
Net Profit (USD MM)
Operating Profit
Highest at USD -125.14 MM
in the last five periodsMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (USD MM)
EPS
Highest at USD -0.68
in the last five periodsMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (USD)
Inventory Turnover Ratio
Highest at 7.28 times
in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its inventory faster
Inventory Turnover Ratio
Debtors Turnover Ratio
Highest at 1.06 times
in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its Debtors faster
Debtors Turnover Ratio
Net Sales
Higher at USD 3.6 MM
than preceding 12 month period ended Jun 2026MOJO Watch
In the nine month period the company has already crossed sales of the previous twelve months
Net Sales (USD MM)
Depreciation
Highest at USD 5.4 MM
in the last five periodsMOJO Watch
The expenditure on assets done by the company may have gone into operation
Depreciation (USD MM)
Depreciation
At USD 5.4 MM has Grown at 89.77%
period on period (QoQ)MOJO Watch
The expenditure on assets done by the company has gone into productive use which should positively reflect in the future sales
Depreciation (USD MM)
Here's what is not working for Denali Therapeutics, Inc.
Operating Cash Flow
Lowest at USD -434.04 MM
in the last three yearsMOJO Watch
The company's cash revenues from business operations are falling
Operating Cash Flows (USD MM)
Cash and Eqv
Lowest at USD 1,698.15 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is deteriorating
Cash and Cash Equivalents
Raw Material Cost
Grown by 5,239% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin
Raw Material Cost as a percentage of Sales
Footer loading
